Clinical Trials
24 trialsNCT07237256 2026-05-26
NoLEEta
UNICANCER
Phase 3 Recruiting
NCT07174336 2026-05-22
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT06760637 2026-05-19
FourLight-3
Pfizer
Phase 3 Active not recruiting
NCT06757634 2026-05-18
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity Inc
Phase 3 Recruiting
NCT07085767 2026-05-15
OPERA-02
Olema Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT05827081 2026-05-14
Adjuvant WIDER
Novartis
Phase 3 Recruiting
NCT06377852 2026-05-13
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
American Society of Clinical Oncology
Phase 3 Recruiting
NCT04055493 2026-05-11
ADAPTcycle
West German Study Group
Phase 3 Active not recruiting
NCT07400523 2026-04-28
Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
NCT04964934 2026-04-21
SERENA-6
AstraZeneca
Phase 3 Active not recruiting
NCT07340658 2026-04-02
SIE-3
Rovi Pharmaceuticals Laboratories
Phase 3 Not yet recruiting
NCT03701334 2026-04-01
NATALEE
Novartis
Phase 3 Active not recruiting
NCT06585969 2026-02-12
DISCORDANT
Danish Breast Cancer Cooperative Group
Phase 3 Withdrawn
NCT05207709 2025-04-29
HARMONIA
SOLTI Breast Cancer Research Group
Phase 3 Active not recruiting
NCT01958021 2025-03-07
MONALEESA-2
Novartis
Phase 3 Completed
NCT03439046 2024-08-01
BioItaLEE
Novartis
Phase 3 Completed
NCT02344472 2024-06-04
Detect V / CHEVENDO (Chemo vs. Endo)
University of Ulm
Phase 3 Active not recruiting
NCT02422615 2023-11-30
MONALEESA-3
Novartis
Phase 3 Completed
NCT02941926 2023-10-24
COMPLEEMENT-1
Novartis
Phase 3 Completed
NCT03462251 2023-01-19
RIBBIT
iOMEDICO AG
Phase 3 Completed
NCT03096847 2021-10-11
Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT03905343 2021-06-16
Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC
Swiss Cancer Institute
Phase 3 Terminated
NCT03050398 2020-05-28
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
Novartis
Phase 3 Terminated
NCT03081234 2018-03-15
EarLEE-2
Novartis
Phase 3 Withdrawn